UF-KURE19 CAR-T cells for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new kind of immune cell therapy called CAR-T cells, which are made from your own blood. It's for people with B-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if this treatment can help shrink or eliminate the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with a type of B-cell lymphoma that is CD19-positive (your cancer cells have a specific protein called CD19).
- For some types (like DLBCL or high-grade), your cancer must have returned after at least 2 prior treatments, or not responded to first treatment, or you are not eligible for a stem cell transplant.
- For other types (like follicular or marginal zone lymphoma), your cancer must have returned after at least 2 prior treatments.
- You must have at least one tumor that can be seen on a PET scan (FDG-avid).
- You must not have had a previous stem cell transplant using someone else's cells, and no prior treatment with CAR-T cells.
- Your heart, liver, and kidney functions must be within a certain range.
- You must not be pregnant or breastfeeding, and if you are of childbearing age, you must agree to use effective birth control during and after treatment.
- You must not have an active infection like HIV or hepatitis B/C, or serious heart, lung, or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
Hear when a new Marginal Zone B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.